Gerald McMahon

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Gabriele Bergers, Rolf A. Brekken, Gerald McMahon et al. · Nature Cell Biology · 2000 · 2.8K citations · Full text

Medicine, Cancer Biology, Oncology +14

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

Medicine, Oncology, Pharmacology +15

Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors

Moosa Mohammadi, Gerald McMahon, Li Sun et al. · Science · 1997 · 1.1K citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

T. Annie T. Fong, Laura K. Shawver, Li Sun et al. · PubMed · 1999 · 1K citations

Medicine, Oncology, Pharmacology +16

Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids

Ker Yu, William Bayona, Caleb B. Kallen et al. · Journal of Biological Chemistry · 1995 · 705 citations · Full text

Life Sciences, Biochemistry, Pharmacology +12